Author: admin

The Neuromyelitis Optica Spectrum Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Neuromyelitis Optica Spectrum Disorder Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuromyelitis Optica Spectrum Disorder Market.

Some of the key takeaways from the Neuromyelitis Optica Spectrum Disorder Pipeline Report:

• Companies across the globe are diligently working toward developing novel Neuromyelitis Optica Spectrum Disorder treatment therapies with a considerable amount of success over the years. 
• Neuromyelitis Optica Spectrum Disorder companies working in the treatment market are Shanghai Pharmaceuticals Holding Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD, Harbour BioMed, Reistone Biopharma, ENDECE, Aeterna Zentaris, RemeGen, Alexion Pharmaceuticals, and others, are developing therapies for the Neuromyelitis Optica Spectrum Disorder treatment 

• Emerging Neuromyelitis Optica Spectrum Disorder therapies in the different phases of clinical trials are- B001, LP-168, HBM9161, SHR1459, NDC-1308, AIM Biologicals, Telitacicept, Ravulizumab, and others are expected to have a significant impact on the Neuromyelitis Optica Spectrum Disorder market in the coming years.   
• In June 2022, Alexion Pharmaceuticals has commenced a Phase II/III multicenter study, designed as an open-label, historical-controlled, single-arm trial. The objective is to assess the efficacy, pharmacokinetics, pharmacodynamics, and safety of ravulizumab in children and adolescents diagnosed with aquaporin-4 antibody positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD).
• In June 2022, The Brazilian Health Regulatory Agency (ANVISA) has granted approval for UPLIZNA as a standalone treatment for adults diagnosed with NMOSD who demonstrate positivity for the AQP4-IgG biomarker.
• In May 2022, Alexion Pharmaceuticals reported that ULTOMIRIS® (ravulizumab-cwvz) achieved the primary endpoint in the CHAMPION-NMOSD Phase III trial involving adults diagnosed with neuromyelitis optica spectrum disorder.
• In May 2022, The European Commission sanctioned UPLIZNA, a medication created by Horizon Therapeutics, for use as a sole treatment for adult individuals diagnosed with neuromyelitis optica spectrum disorder (NMOSD). This approval covers all adult NMOSD patients, irrespective of their AQP4-IgG biomarker test results.

Neuromyelitis Optica Spectrum Disorder Overview

Devic disease, also known as neuromyelitis optic spectrum disorder (NMOSD), is a chronic brain and spinal cord ailment characterized by inflammation of the spinal cord (myelitis) and optic nerve (optic neuritis).

Get a Free Sample PDF Report to know more about Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight

Emerging Neuromyelitis Optica Spectrum Disorder Drugs Under Different Phases of Clinical Development Include:

• NDC-1308: ENDECE
• AIM Biologicals: Aeterna Zentaris
• B001: Shanghai Pharmaceuticals Holding Co., Ltd.
• LP-168: Guangzhou Lupeng Pharmaceutical Company LTD
• HBM9161: Harbour BioMed
• SHR1459: Reistone Biopharma
• Telitacicept: RemeGen
• Ravulizumab: Alexion Pharmaceuticals

Neuromyelitis Optica Spectrum Disorder Route of Administration

Neuromyelitis Optica Spectrum Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intravenous
• Oral
• Subcutaneous
• Molecule Type

Neuromyelitis Optica Spectrum Disorder Molecule Type

Neuromyelitis Optica Spectrum Disorder Products have been categorized under various Molecule types, such as

• Immunoglobulin
• Monoclonal antibodies
• Protein
• Recombinant fusion proteins
• Small molecules
• Vaccine
• Product Type

Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutics Assessment

• Neuromyelitis Optica Spectrum Disorder Assessment by Product Type
• Neuromyelitis Optica Spectrum Disorder By Stage and Product Type
• Neuromyelitis Optica Spectrum Disorder Assessment by Route of Administration
• Neuromyelitis Optica Spectrum Disorder By Stage and Route of Administration
• Neuromyelitis Optica Spectrum Disorder Assessment by Molecule Type
• Neuromyelitis Optica Spectrum Disorder by Stage and Molecule Type

DelveInsight’s Neuromyelitis Optica Spectrum Disorder Report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Neuromyelitis Optica Spectrum Disorder product details are provided in the report. Download the Neuromyelitis Optica Spectrum Disorder pipeline report to learn more about the emerging Neuromyelitis Optica Spectrum Disorder therapies

Some of the key companies in the Neuromyelitis Optica Spectrum Disorder Therapeutics Market include:

Key companies developing therapies for Neuromyelitis Optica Spectrum Disorder are – Hoffmann-La Roche Ltd, Horizon Therapeutics plc (Viela Bio), AstraZeneca, Mitsubishi Tanabe Pharma, Harbour BioMed, RemeGen, Teva Pharmaceutical Industries Ltd, Horizon Therapeutics plc, TG Therapeutics, Opexa Therapeutics, and others.

Neuromyelitis Optica Spectrum Disorder Pipeline Analysis:

The Neuromyelitis Optica Spectrum Disorder pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Neuromyelitis Optica Spectrum Disorder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuromyelitis Optica Spectrum Disorder Treatment.
• Neuromyelitis Optica Spectrum Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Neuromyelitis Optica Spectrum Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuromyelitis Optica Spectrum Disorder market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Neuromyelitis Optica Spectrum Disorder drugs and therapies

Neuromyelitis Optica Spectrum Disorder Pipeline Market Drivers

• Increase in NMOSD prevalence, rising awareness among general population about NMOSD• Emergence of novel therapies are some of the important factors that are fueling the Neuromyelitis Optica Spectrum Disorder Market.

Neuromyelitis Optica Spectrum Disorder Pipeline Market Barriers

• However, dearth of skilled professionals and lack of healthcare infrastructure in developing economies, high costs for NMOSD treatment and other factors are creating obstacles in the Neuromyelitis Optica Spectrum Disorder Market growth.

Scope of Neuromyelitis Optica Spectrum Disorder Pipeline Drug Insight    

• Coverage: Global
• Key Neuromyelitis Optica Spectrum Disorder Companies: Shanghai Pharmaceuticals Holding Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD, Harbour BioMed, Reistone Biopharma, ENDECE, Aeterna Zentaris, RemeGen, Alexion Pharmaceuticals, and others
• Key Neuromyelitis Optica Spectrum Disorder Therapies: B001, LP-168, HBM9161, SHR1459, NDC-1308, AIM Biologicals, Telitacicept, Ravulizumab, and others
• Neuromyelitis Optica Spectrum Disorder Therapeutic Assessment: Neuromyelitis Optica Spectrum Disorder current marketed and Neuromyelitis Optica Spectrum Disorder emerging therapies
• Neuromyelitis Optica Spectrum Disorder Market Dynamics: Neuromyelitis Optica Spectrum Disorder market drivers and Neuromyelitis Optica Spectrum Disorder market barriers 

Request for Sample PDF Report for Neuromyelitis Optica Spectrum Disorder Pipeline Assessment and clinical trials

Table of Contents

1. Neuromyelitis Optica Spectrum Disorder Report Introduction

2. Neuromyelitis Optica Spectrum Disorder Executive Summary

3. Neuromyelitis Optica Spectrum Disorder Overview

4. Neuromyelitis Optica Spectrum Disorder- Analytical Perspective In-depth Commercial Assessment

5. Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutics

6. Neuromyelitis Optica Spectrum Disorder Late Stage Products (Phase II/III)

7. Neuromyelitis Optica Spectrum Disorder Mid Stage Products (Phase II)

8. Neuromyelitis Optica Spectrum Disorder Early Stage Products (Phase I)

9. Neuromyelitis Optica Spectrum Disorder Preclinical Stage Products

10. Neuromyelitis Optica Spectrum Disorder Therapeutics Assessment

11. Neuromyelitis Optica Spectrum Disorder Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Neuromyelitis Optica Spectrum Disorder Key Companies

14. Neuromyelitis Optica Spectrum Disorder Key Products

15. Neuromyelitis Optica Spectrum Disorder Unmet Needs

16 . Neuromyelitis Optica Spectrum Disorder Market Drivers and Barriers

17. Neuromyelitis Optica Spectrum Disorder Future Perspectives and Conclusion

18. Neuromyelitis Optica Spectrum Disorder Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Neuromyelitis Optica Spectrum Disorder Pipeline Analysis, 2023 Updates | Latest FDA, EMA, and PMDA Approvals | Roche Ltd, Horizon Therapeutics plc (Viela Bio), AstraZeneca, Mitsubishi Tanabe Pharma

“Pulmonary Hypertension Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Pulmonary Hypertension pipeline constitutes 80+ key companies continuously working towards developing 80+ Pulmonary Hypertension treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Pulmonary Hypertension Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Pulmonary Hypertension Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pulmonary Hypertension Market.

Some of the key takeaways from the Pulmonary Hypertension Pipeline Report:

• Companies across the globe are diligently working toward developing novel Pulmonary Hypertension treatment therapies with a considerable amount of success over the years. 
• Pulmonary Hypertension companies working in the treatment market are Topadur Pharma, Centessa Pharmaceuticals, Ribomic, Gmax Biopharm, ATXA Therapeutics, Aerami Therapeutics, PhaseBio Pharmaceuticals, Altavant Sciences, Respira Therapeutics, Pharmosa Biopharm, Merck, Arena Pharmaceuticals/United Therapeutics, Bial – Portela C S.A., Respira Therapeutics, Gmax Biopharm, Aerami Therapeutics, Centessa Pharmaceuticals, and others, are developing therapies for the Pulmonary Hypertension treatment 

• Emerging Pulmonary Hypertension therapies in the different phases of clinical trials are- TOP V122, MGX292, RBM-011, Getagozumab, NTP42, AER-901, Pemziviptadil (PB1046), Rodatristat Ethyl, RT234, L606, Sotatercept, Ralinepag, Zamicastat, RT234, GMA301, AER-901, MGX 292, and others are expected to have a significant impact on the Pulmonary Hypertension market in the coming years.   
• In July 2022, The Phase II research for the medication candidate CS1 for pulmonary arterial hypertension (PAH) has begun, according to a report from Cereno Scientific. The study’s timeframe has been modified by nearly a quarter, and top-line results are now anticipated for Q1 2023 based on the timing of enrolment and a number of variables, most of which are connected to the activation of clinical sites. To help achieve the Q1 deadline, the number of study sites has been increased to include around 10 clinics across the US, with room for future growth.
• In June 2022, Key preclinical data confirming seralutinib’s potential for the treatment of pulmonary arterial hypertension (PAH) were published, according to a statement from Gossamer Bio, Inc. With improved cardiac hemodynamics, decreased NT-proBNP, reverse remodelling of pulmonary vascular disease, and improved inflammatory biomarkers, inhaled seralutinib was an effective treatment for severe PAH in two animal models. In a preclinical research, seralutinib outperformed imatinib in terms of efficacy.
• In June 2022, At the Pulmonary Hypertension Association International Conference and Scientific Sessions, which took place from June 10 through 12, 2022, Keros Therapeutics, Inc. presented findings from a preclinical study of RKER-012 on cardiac and pulmonary pathology in an established rodent model of pulmonary arterial hypertension (“PAH”).
• In June 2022, As a potentially life-saving treatment for patients with acute pulmonary hypertension following cardiac surgery, Attgeno AB recently announced that it had received approval from the Swedish Medical Products Agency and the Swedish Ethical Review Authority to begin a phase 2 clinical trial of its lead drug candidate Supernitro.
• In May 2022, At the American Thoracic Society (ATS) International Conference in San Francisco, Aerovate Therapeutics, Inc. presented Phase 1 findings. According to Aerovate’s research, AV-101, a brand-new imatinib inhalation dry powder formulation, was generally well tolerated by healthy adult volunteers. No major side effects were noted. As important aspects of the pathogenesis of PAH, cellular hyperproliferation and resistance to apoptosis in the pulmonary vasculature are being addressed by the development of AV-101.
• In May 2022, Results from an animal model of pulmonary arterial hypertension (PAH) that compared rodatristat ethyl as a monotherapy and in conjunction with the type A endothelin receptor antagonist, ambrisentan, were presented by Altavant Sciences. At ATS 2022, which was held in San Francisco, California, from May 13–18, 2022, results detailing changes in post-hypoxia occlusions and mean pulmonary arterial pressure (mPAP) with each treatment regimen were presented in a poster.
• In April 2022, The multicenter trial of Respira Therapeutics‘ principal product candidate, RT234-PAH (vardenafil delivered as a dry powder inhalation therapy), saw the first patient in the United States receive a dosage. Two successive cohorts of the VIPAH-PRN 2b trial (Vardenafil Inhaled for Pulmonary Arterial Hypertension – PRN) will be given single doses of RT234 via an Axial Oscillating Sphere dry powder inhaler. The objective of the trial is to assess the safety and preliminary efficacy of RT234 in treating PAH patients with New York Heart Association (NYHA) Functional Class II–III symptoms for acutely improving episodic symptoms and exercise capacity.
• In March 2022, An study titled “BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Study” was published in the esteemed American Journal of Respiratory and Critical Care Medicine, according to a press release from Resverlogix Corp. The article describes apabetalone’s beneficial effects in the investigator-led APPRoAcH-p pilot research for pulmonary arterial hypertension (PAH).
• In March 2022, In order to assess the effectiveness of Sotatercept when combined with background pulmonary arterial hypertension (PAH) therapy in newly diagnosed intermediate- and high-risk PAH patients, Acceleron Pharma began a Phase 3 randomised, double-blind, placebo-controlled research.
• In November 2021, The successful completion of the acquisition of Acceleron Pharma Inc. was announced by Merck, also known as MSD outside of the United States and Canada.

Pulmonary Hypertension Overview

Elevated pulmonary vascular resistance is a defining characteristic of the broad group of illnesses known as pulmonary hypertension. Patients frequently exhibit vague symptoms such as increasing weakness and dyspnea with exertion. The management of symptoms and the therapy of underlying disorders are the main goals of treatment for the progressive disease known as pulmonary hypertension.

Get a Free Sample PDF Report to know more about Pulmonary Hypertension Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/pulmonary-hypertension-pipeline-insight

Emerging Pulmonary Hypertension Drugs Under Different Phases of Clinical Development Include:

• TOP V122: Topadur Pharma
• MGX292: Centessa Pharmaceuticals
• RBM-011: Ribomic
• Getagozumab: Gmax Biopharm
• NTP42: ATXA Therapeutics
• AER-901: Aerami Therapeutics
• Pemziviptadil (PB1046): PhaseBio Pharmaceuticals
• Rodatristat Ethyl: Altavant Sciences
• RT234: Respira Therapeutics
• L606: Pharmosa Biopharm
• Sotatercept: Merck
• Ralinepag: Arena Pharmaceuticals/United Therapeutics
• Zamicastat: Bial – Portela C S.A.
• RT234: Respira Therapeutics
• GMA301: Gmax Biopharm
• AER-901: Aerami Therapeutics
• RBM-011: Ribomic
• MGX 292: Centessa Pharmaceuticals

Pulmonary Hypertension Route of Administration

Pulmonary Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Pulmonary Hypertension Molecule Type

Pulmonary Hypertension Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Pulmonary Hypertension Pipeline Therapeutics Assessment

• Pulmonary Hypertension Assessment by Product Type
• Pulmonary Hypertension By Stage and Product Type
• Pulmonary Hypertension Assessment by Route of Administration
• Pulmonary Hypertension By Stage and Route of Administration
• Pulmonary Hypertension Assessment by Molecule Type
• Pulmonary Hypertension by Stage and Molecule Type

DelveInsight’s Pulmonary Hypertension Report covers around 80+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Pulmonary Hypertension product details are provided in the report. Download the Pulmonary Hypertension pipeline report to learn more about the emerging Pulmonary Hypertension therapies

Some of the key companies in the Pulmonary Hypertension Therapeutics Market include:

Key companies developing therapies for Pulmonary Hypertension are – Reata Pharmaceuticals, Pharmosa BioPharm, United Therapeutics Corporation, Acceleron Pharma, Bellerophon Therapeutics, Northern Therapeutics, Merck Sharp & Dohme Corp., Apeiron Biologics, Abraxis Bioscience, Bayer, Novartis, Aerovate Therapeutics, Cereno Scientific AB, Gossamer Bio, Altavant Sciences GmbH, Gmax Biopharm LLC., Respira Therapeutics, Resverlogix Corp, Aerami Therapeutics, Vigonvita Life Sciences, Ribomic, Corsair Pharma, Centessa Pharmaceuticals, Biozeus, Topadur Pharma, and others.

Pulmonary Hypertension Pipeline Analysis:

The Pulmonary Hypertension pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Hypertension with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Hypertension Treatment.
• Pulmonary Hypertension key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pulmonary Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Hypertension market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pulmonary Hypertension drugs and therapies

Pulmonary Hypertension Pipeline Market Drivers

• Rising prevalence of Pulmonary Hypertension worldwide, increasing investment for healthcare infrastructure, robust Drug pipeline and the new product combinations are some of the important factors that are fueling the Pulmonary Hypertension Market.

Pulmonary Hypertension Pipeline Market Barriers 

• However, high cost associated with the treatment of Pulmonary Hypertension, lack of awareness among people in developing countries and other factors are creating obstacles in the Pulmonary Hypertension Market growth.

Scope of Pulmonary Hypertension Pipeline Drug Insight    

• Coverage: Global
• Key Pulmonary Hypertension Companies: Topadur Pharma, Centessa Pharmaceuticals, Ribomic, Gmax Biopharm, ATXA Therapeutics, Aerami Therapeutics, PhaseBio Pharmaceuticals, Altavant Sciences, Respira Therapeutics, Pharmosa Biopharm, Merck, Arena Pharmaceuticals/United Therapeutics, Bial – Portela C S.A., Respira Therapeutics, Gmax Biopharm, Aerami Therapeutics, Centessa Pharmaceuticals, and others
• Key Pulmonary Hypertension Therapies: TOP V122, MGX292, RBM-011, Getagozumab, NTP42, AER-901, Pemziviptadil (PB1046), Rodatristat Ethyl, RT234, L606, Sotatercept, Ralinepag, Zamicastat, RT234, GMA301, AER-901, MGX 292, and others
• Pulmonary Hypertension Therapeutic Assessment: Pulmonary Hypertension current marketed and Pulmonary Hypertension emerging therapies
• Pulmonary Hypertension Market Dynamics: Pulmonary Hypertension market drivers and Pulmonary Hypertension market barriers 

Request for Sample PDF Report for Pulmonary Hypertension Pipeline Assessment and clinical trials

Table of Contents 

1. Pulmonary Hypertension Report Introduction

2. Pulmonary Hypertension Executive Summary

3. Pulmonary Hypertension Overview

4. Pulmonary Hypertension- Analytical Perspective In-depth Commercial Assessment

5. Pulmonary Hypertension Pipeline Therapeutics

6. Pulmonary Hypertension Late Stage Products (Phase II/III)

7. Pulmonary Hypertension Mid Stage Products (Phase II)

8. Pulmonary Hypertension Early Stage Products (Phase I)

9. Pulmonary Hypertension Preclinical Stage Products

10. Pulmonary Hypertension Therapeutics Assessment

11. Pulmonary Hypertension Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Pulmonary Hypertension Key Companies

14. Pulmonary Hypertension Key Products

15. Pulmonary Hypertension Unmet Needs

16 . Pulmonary Hypertension Market Drivers and Barriers

17. Pulmonary Hypertension Future Perspectives and Conclusion

18. Pulmonary Hypertension Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pulmonary Hypertension Pipeline Review 2023: Comprehensive Analysis of Emerging Medications, Recent FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Prospects by DelveInsight

“Nonmelanoma Skin Cancer Market”

(Albany, USA) DelveInsight’s “Nonmelanoma Skin Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Nonmelanoma Skin Cancer, historical and forecasted epidemiology as well as the Nonmelanoma Skin Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Nonmelanoma Skin Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Nonmelanoma Skin Cancer Market Forecast

Some of the key facts of the Nonmelanoma Skin Cancer Market Report: 

• The Nonmelanoma Skin Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Skin cancer is the most typical cancer, according to Cedars-Sinai (n.d.). Skin cancer accounts for between 40 and 50 percent of all cancer cases detected each year
• Goldenberg et al. (2016) conducted a retrospective cohort analysis using Truven Health MarketScan database insurance claims, enrolling patients 18 years of age or older with two or more BCC claims that were at least 30 days apart between October 2011 and September 2012. The age-adjusted prevalence rate for BCC patients was 342.64 per 100,000. The prevalence rates were higher in males than in females, higher in patients 65 years of age or older, and lowest in patients 18 to 24 years of age
• STP705, AIV001, RP1, and other new treatments for non-melanoma skin cancer (NMSC) are available. The market will be driven by the approval of these therapies because it will give patients new and varied treatment options
• Key Nonmelanoma Skin Cancer Companies: Sirnaomics, AiViva BioPharma, Replimune, Ortho Dermatologics, Philogen S.p.A., AstraZeneca, Pfizer, and others
• Key Nonmelanoma Skin Cancer Therapies: STP705, AIV001, RP1, Tretinoin 0.1%, L19IL2 +L19TNF, Iressa, sirolimus, and others
• The Nonmelanoma Skin Cancer epidemiology based on gender analyzed that Men are two times more likely than women to develop basal cell carcinoma and three times more likely to develop squamous cell carcinoma than Women
• The Nonmelanoma Skin Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Nonmelanoma Skin Cancer pipeline products will significantly revolutionize the Nonmelanoma Skin Cancer market dynamics.

Nonmelanoma Skin Cancer Overview

Skin tumours that don’t start out as melanoma are referred to as non-melanoma skin cancer. These more typical types of skin cancer are distinguished from the less frequent melanoma, which spreads more quickly in the body, by the name “non-melanoma.”

Get a Free sample for the Nonmelanoma Skin Cancer Market Report 

https://www.delveinsight.com/report-store/nonmelanoma-skin-cancer-market

Nonmelanoma Skin Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Nonmelanoma Skin Cancer Epidemiology Segmentation:

The Nonmelanoma Skin Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Nonmelanoma Skin Cancer
• Prevalent Cases of Nonmelanoma Skin Cancer by severity
• Gender-specific Prevalence of Nonmelanoma Skin Cancer
• Diagnosed Cases of Episodic and Chronic Nonmelanoma Skin Cancer

Download the report to understand which factors are driving Nonmelanoma Skin Cancer epidemiology trends @ Nonmelanoma Skin Cancer Epidemiology Forecast

Nonmelanoma Skin Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Nonmelanoma Skin Cancer market or expected to get launched during the study period. The analysis covers Nonmelanoma Skin Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Nonmelanoma Skin Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Nonmelanoma Skin Cancer Therapies and Key Companies

• STP705: Sirnaomics
• AIV001: AiViva BioPharma
• RP1: Replimune
• Tretinoin 0.1%: Ortho Dermatologics
• L19IL2 +L19TNF: Philogen S.p.A.
• Iressa: AstraZeneca
• sirolimus: Pfizer

Discover more about therapies set to grab major Nonmelanoma Skin Cancer market share @ Nonmelanoma Skin Cancer Treatment Market

Scope of the Nonmelanoma Skin Cancer Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Nonmelanoma Skin Cancer Companies: Sirnaomics, AiViva BioPharma, Replimune, Ortho Dermatologics, Philogen S.p.A., AstraZeneca, Pfizer, and others
• Key Nonmelanoma Skin Cancer Therapies: STP705, AIV001, RP1, Tretinoin 0.1%, L19IL2 +L19TNF, Iressa, sirolimus, and others
• Nonmelanoma Skin Cancer Therapeutic Assessment: Nonmelanoma Skin Cancer current marketed and Nonmelanoma Skin Cancer emerging therapies
• Nonmelanoma Skin Cancer Market Dynamics: Nonmelanoma Skin Cancer market drivers and Nonmelanoma Skin Cancer market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Nonmelanoma Skin Cancer Unmet Needs, KOL’s views, Analyst’s views, Nonmelanoma Skin Cancer Market Access and Reimbursement 

To know more about Nonmelanoma Skin Cancer companies working in the treatment market, visit @ Nonmelanoma Skin Cancer Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Nonmelanoma Skin Cancer Market Report Introduction

2. Executive Summary for Nonmelanoma Skin Cancer

3. SWOT analysis of Nonmelanoma Skin Cancer

4. Nonmelanoma Skin Cancer Patient Share (%) Overview at a Glance

5. Nonmelanoma Skin Cancer Market Overview at a Glance

6. Nonmelanoma Skin Cancer Disease Background and Overview

7. Nonmelanoma Skin Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Nonmelanoma Skin Cancer 

9. Nonmelanoma Skin Cancer Current Treatment and Medical Practices

10. Nonmelanoma Skin Cancer Unmet Needs

11. Nonmelanoma Skin Cancer Emerging Therapies

12. Nonmelanoma Skin Cancer Market Outlook

13. Country-Wise Nonmelanoma Skin Cancer Market Analysis (2019–2032)

14. Nonmelanoma Skin Cancer Market Access and Reimbursement of Therapies

15. Nonmelanoma Skin Cancer Market Drivers

16. Nonmelanoma Skin Cancer Market Barriers

17.  Nonmelanoma Skin Cancer Appendix

18. Nonmelanoma Skin Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Projected Surge in Growth for Nonmelanoma Skin Cancer Market (2023-2032): Detailed Analysis by DelveInsight | AstraZeneca, Pfizer, Replimune, Ortho Dermatologics, Philogen S.p.A.

“Stem Cell Mobilization Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Stem Cell Mobilization pipeline constitutes key companies continuously working towards developing Stem Cell Mobilization treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Stem Cell Mobilization Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Stem Cell Mobilization Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Stem Cell Mobilization Market.

Some of the key takeaways from the Stem Cell Mobilization Pipeline Report:

• Companies across the globe are diligently working toward developing novel Stem Cell Mobilization treatment therapies with a considerable amount of success over the years. 
• Stem Cell Mobilization companies working in the treatment market are Aviara Pharmaceuticals, Spexis, TaiGen Biotechnology, Magenta Therapeutics, BioLineRx, and others, are developing therapies for the Stem Cell Mobilization treatment 

• Emerging Stem Cell Mobilization therapies in the different phases of clinical trials are- AVA4746, Balixafortide, Burixafor, MGTA 145, Motixafortide, and others are expected to have a significant impact on the Stem Cell Mobilization market in the coming years.   
• In April 2023, A trial titled “A Pilot Safety and Feasibility Study to EvaluateMotixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) as a Novel Regimen toMobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)” was started by BioLineRx, Ltd.
• In November 2022, The FDA has accepted for review and filed the company’s New Drug Application (NDA) for APHEXDA® (motixafortide) in stem cell mobilisation for autologous transplantation in multiple myeloma patients, according to a statement from BioLineRx Ltd.

Stem Cell Mobilization Overview

In the treatment of severe ischemic illnesses such myocardial infarction, limb ischemia, ischemic stroke, and acute kidney injury, stem cell mobilization is crucial. The outflow of diverse stem cells from the bone marrow into the peripheral circulation is known as stem cell mobilization.

Get a Free Sample PDF Report to know more about Stem Cell Mobilization Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/stem-cell-mobilization-pipeline-insight

Emerging Stem Cell Mobilization Drugs Under Different Phases of Clinical Development Include:

• AVA4746: Aviara Pharmaceuticals
• Balixafortide: Spexis
• Burixafor: TaiGen Biotechnology
• MGTA 145: Magenta Therapeutics
• Motixafortide: BioLineRx 

Stem Cell Mobilization Pipeline Therapeutics Assessment

• Stem Cell Mobilization Assessment by Product Type
• Stem Cell Mobilization By Stage and Product Type
• Stem Cell Mobilization Assessment by Route of Administration
• Stem Cell Mobilization By Stage and Route of Administration
• Stem Cell Mobilization Assessment by Molecule Type
• Stem Cell Mobilization by Stage and Molecule Type

DelveInsight’s Stem Cell Mobilization Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Stem Cell Mobilization product details are provided in the report. Download the Stem Cell Mobilization pipeline report to learn more about the emerging Stem Cell Mobilization therapies

Some of the key companies in the Stem Cell Mobilization Therapeutics Market include:

Key companies developing therapies for Stem Cell Mobilization are – Sanofi Genzyme, Amgen, Teva Pharmaceuticals, Genentech, Pfizer, Novartis, Celgene, BioLineRx, HemaCare, Gamida Cell, RegenMed Systems, and others.

Stem Cell Mobilization Pipeline Analysis:

The Stem Cell Mobilization pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Stem Cell Mobilization with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Stem Cell Mobilization Treatment.
• Stem Cell Mobilization key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Stem Cell Mobilization Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Stem Cell Mobilization market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Stem Cell Mobilization drugs and therapies

Stem Cell Mobilization Pipeline Market Drivers

• Increase in prevalence of Solid Tumors, novel pathways being explored in animal and early human studies are some of the important factors that are fueling the Stem Cell Mobilization Market.

Stem Cell Mobilization Pipeline Market Barriers

• However, high cost of therapy, challenges associated with the analysis of genetic factors responsible for the great variability in mobilization responses, poor Understanding of the mechanisms underlying the process of HSPC mobilization and other factors are creating obstacles in the Stem Cell Mobilization Market growth.

Scope of Stem Cell Mobilization Pipeline Drug Insight    

• Coverage: Global
• Key Stem Cell Mobilization Companies: Aviara Pharmaceuticals, Spexis, TaiGen Biotechnology, Magenta Therapeutics, BioLineRx, and others
• Key Stem Cell Mobilization Therapies: AVA4746, Balixafortide, Burixafor, MGTA 145, Motixafortide, and others
• Stem Cell Mobilization Therapeutic Assessment: Stem Cell Mobilization current marketed and Stem Cell Mobilization emerging therapies
• Stem Cell Mobilization Market Dynamics: Stem Cell Mobilization market drivers and Stem Cell Mobilization market barriers 

Request for Sample PDF Report for Stem Cell Mobilization Pipeline Assessment and clinical trials

Table of Contents 

1. Stem Cell Mobilization Report Introduction

2. Stem Cell Mobilization Executive Summary

3. Stem Cell Mobilization Overview

4. Stem Cell Mobilization- Analytical Perspective In-depth Commercial Assessment

5. Stem Cell Mobilization Pipeline Therapeutics

6. Stem Cell Mobilization Late Stage Products (Phase II/III)

7. Stem Cell Mobilization Mid Stage Products (Phase II)

8. Stem Cell Mobilization Early Stage Products (Phase I)

9. Stem Cell Mobilization Preclinical Stage Products

10. Stem Cell Mobilization Therapeutics Assessment

11. Stem Cell Mobilization Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Stem Cell Mobilization Key Companies

14. Stem Cell Mobilization Key Products

15. Stem Cell Mobilization Unmet Needs

16 . Stem Cell Mobilization Market Drivers and Barriers

17. Stem Cell Mobilization Future Perspectives and Conclusion

18. Stem Cell Mobilization Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Stem Cell Mobilization Pipeline 2023: Latest FDA, EMA, and PMDA Approvals, Innovative Therapies, Ongoing Clinical Trials, and Treatment by Aviara Pharmaceuticals, Spexis, TaiGen Biotech

“Bone Metastasis in Solid Tumors Market”

DelveInsight’s “Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Bone Metastasis in Solid Tumors, historical and forecasted epidemiology as well as the Bone Metastasis in Solid Tumors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Bone Metastasis in Solid Tumors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bone Metastasis in Solid Tumors Market Forecast

Some of the key facts of the Bone Metastasis in Solid Tumors Market Report: 

• The Bone Metastasis in Solid Tumors market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The rate of bone metastases is 23.19% in SCLC, 22.50% in NSCLC (NOS/others), 20.28% in ADC, 8.44% in squamous cell carcinoma of the lung (SCC), and 4.11% in bronchioloalveolar carcinoma [NSCLC (BAC)] according to the study by Huang et al. (2020)
• Metastatic bone disease is frequently seen in specific cancer types, particularly in metastasis arising from the breast (70%), prostate (85%), lung (40%), and kidney (40%) cancer types, according to a study by Coleman et al. (2020)
• Approximately 400,000 new cases of malignant bone metastasis are identified in the US each year, according to the American Cancer Society (ACS). Additionally, according to the ACS, people with advanced prostate cancer and breast cancer are more likely than other patients to have malignant tumours with bone metastases (30–75%)
• According to a study by Ryan et al. (2022), 5.1% of cancer patients in the SEER database had bone metastasis diagnoses, which equates to about 18.8 per 100,000 diagnoses in the US every year from 2010 to 2015. In this study, men made up 57.8% of the patients with solid tumours that had bone metastases
• The development of NanaBis is currently moving forward in Phase III at Medlab, and if the tests are successful, an FDA NDA application might be submitted by the end of 2024
• Key Bone Metastasis in Solid Tumors Companies: NanaBis, Actuate Therapeutics, Mabwell Bioscience, Hoffmann-La Roche, Novartis, Upjohn, INSYS Therapeutics Inc, and others
• Key Bone Metastasis in Solid Tumors Therapies: Medlab Clinical, Elraglusib, MW032, Ibandronate, Zoledronic acid, Fragmin, Fentanyl sublingual spray, and others
• The Bone Metastasis in Solid Tumors epidemiology based on gender analyzed that men are more likely to develop bone metastasis in solid tumors than females
• The Bone Metastasis in Solid Tumors market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bone Metastasis in Solid Tumors pipeline products will significantly revolutionize the Bone Metastasis in Solid Tumors market dynamics.

Bone Metastasis in Solid Tumors Overview

When cancer cells migrate from their primary site to a bone, this is known as bone metastasis. Almost all cancers have the ability to “metastasize” (spread) to the bones. However, some cancers, such as breast cancer and prostate cancer, are more prone than others to spread to the bone.

Get a Free sample for the Bone Metastasis in Solid Tumors Market Report 

https://www.delveinsight.com/report-store/bone-metastasis-in-solid-tumors-market

Bone Metastasis in Solid Tumors Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Bone Metastasis in Solid Tumors Epidemiology Segmentation:

The Bone Metastasis in Solid Tumors market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Bone Metastasis in Solid Tumors
• Prevalent Cases of Bone Metastasis in Solid Tumors by severity
• Gender-specific Prevalence of Bone Metastasis in Solid Tumors
• Diagnosed Cases of Episodic and Chronic Bone Metastasis in Solid Tumors

Download the report to understand which factors are driving Bone Metastasis in Solid Tumors epidemiology trends @ Bone Metastasis in Solid Tumors Epidemiology Forecast

Bone Metastasis in Solid Tumors Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bone Metastasis in Solid Tumors market or expected to get launched during the study period. The analysis covers Bone Metastasis in Solid Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Bone Metastasis in Solid Tumors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Bone Metastasis in Solid Tumors Therapies and Key Companies

• Medlab Clinical: NanaBis
• Elraglusib: Actuate Therapeutics
• MW032: Mabwell Bioscience
• Ibandronate: Hoffmann-La Roche
• Zoledronic acid: Novartis
• Fragmin: Upjohn
• Fentanyl sublingual spray: INSYS Therapeutics Inc

Discover more about therapies set to grab major Bone Metastasis in Solid Tumors market share @ Bone Metastasis in Solid Tumors Treatment Market

Scope of the Bone Metastasis in Solid Tumors Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Bone Metastasis in Solid Tumors Companies: NanaBis, Actuate Therapeutics, Mabwell Bioscience, Hoffmann-La Roche, Novartis, Upjohn, INSYS Therapeutics Inc, and others
• Key Bone Metastasis in Solid Tumors Therapies: Medlab Clinical, Elraglusib, MW032, Ibandronate, Zoledronic acid, Fragmin, Fentanyl sublingual spray, and others
• Bone Metastasis in Solid Tumors Therapeutic Assessment: Bone Metastasis in Solid Tumors current marketed and Bone Metastasis in Solid Tumors emerging therapies
• Bone Metastasis in Solid Tumors Market Dynamics: Bone Metastasis in Solid Tumors market drivers and Bone Metastasis in Solid Tumors market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Bone Metastasis in Solid Tumors Unmet Needs, KOL’s views, Analyst’s views, Bone Metastasis in Solid Tumors Market Access and Reimbursement 

To know more about Bone Metastasis in Solid Tumors companies working in the treatment market, visit @ Bone Metastasis in Solid Tumors Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Bone Metastasis in Solid Tumors Market Report Introduction

2. Executive Summary for Bone Metastasis in Solid Tumors

3. SWOT analysis of Bone Metastasis in Solid Tumors

4. Bone Metastasis in Solid Tumors Patient Share (%) Overview at a Glance

5. Bone Metastasis in Solid Tumors Market Overview at a Glance

6. Bone Metastasis in Solid Tumors Disease Background and Overview

7. Bone Metastasis in Solid Tumors Epidemiology and Patient Population

8. Country-Specific Patient Population of Bone Metastasis in Solid Tumors 

9. Bone Metastasis in Solid Tumors Current Treatment and Medical Practices

10. Bone Metastasis in Solid Tumors Unmet Needs

11. Bone Metastasis in Solid Tumors Emerging Therapies

12. Bone Metastasis in Solid Tumors Market Outlook

13. Country-Wise Bone Metastasis in Solid Tumors Market Analysis (2019–2032)

14. Bone Metastasis in Solid Tumors Market Access and Reimbursement of Therapies

15. Bone Metastasis in Solid Tumors Market Drivers

16. Bone Metastasis in Solid Tumors Market Barriers

17.  Bone Metastasis in Solid Tumors Appendix

18. Bone Metastasis in Solid Tumors Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bone Metastasis in Solid Tumors Market 2032 – Epidemiology, Pipeline, Therapies and Recent Regulatory Approvals by DelveInsight | Companies: Mabwell Bioscience, Hoffmann-La Roche, Novartis, Upjohn

The Bladder cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Bladder cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bladder cancer Market.

Some of the key takeaways from the Bladder cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Bladder cancer treatment therapies with a considerable amount of success over the years. 
• Bladder cancer companies working in the treatment market are Ractigen Therapeutics, XNK Therapeutics, Vaxiion Therapeutics, Vyriad, Inc., Istari Oncology Inc., Theralase Technologies Inc., Taiho Oncology, Inc., Lepu Biopharma CO.,Ltd., Janssen Research & Development, LLC, Asieris Pharmaceuticals, ImmunityBio, CG Oncology, UroGen, G1 Therapeutics, BeiGene, and others, are developing therapies for the Bladder cancer treatment 

• Emerging Bladder cancer therapies in the different phases of clinical trials are- RAG-01, XNK03, VAX014, MV-NIS, Lerapolturev, TLD-1433, Futibatinib, HX-008, TAR-200, APL-1202, N-803, CG0070, UGN-102, Trilaciclib, Tislelizumab, and others are expected to have a significant impact on the Bladder cancer market in the coming years.   
• In July 2022, The FDA has acknowledged receipt of a Biologics License Application (BLA) submitted by ImmunityBio, Inc. (NASDAQ: IBRX), for its antibody cytokine fusion protein proposed as a therapy for patients diagnosed with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) accompanied by Ta or T1 disease or without. ImmunityBio, a prominent clinical-stage immunotherapy company, filed the BLA citing promising outcomes from various studies on the investigational treatment, including the ongoing QUILT 3.032 trial. The Prescription Drug User Fee Act (PDUFA) target action date is slated for May 23, 2023.
• In June 2022, CG Oncology disclosed preliminary findings from two ongoing clinical investigations to be showcased at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. The initial presentation focuses on efficacy and safety outcomes from a global Phase 2 study (CORE1) assessing CG0070 combined with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for treating patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG). The second presentation centers on a Phase 1b/2 study (CORE2) investigating CG0070 combined with OPDIVO® (nivolumab) as a neoadjuvant immunotherapy for Muscle-Invasive Bladder Cancer (MIBC) in cisplatin-ineligible patients.
• In July 2022, Nanostics Inc. initiated a prospective clinical research endeavor aimed at confirming the efficacy of ClarityDX Bladder, a pioneering and less invasive diagnostic test for bladder cancer. This study leverages Nanostics’ ClarityDX diagnostic platform and is conducted in collaboration with the University of Alberta’s Alberta Prostate Cancer Research Initiative (APCaRI) and DynaLIFE Medical Labs.
• In May 2022, Asieris Pharmaceuticals disclosed that the ANTICIPATE Study will be showcased at the 2022 American Society of Clinical Oncology (ASCO) annual meeting held from June 3-7, 2022, in Chicago. The study evaluates the administration of oral APL-1202 combined with BeiGene’s tislelizumab versus the sole use of tislelizumab as neoadjuvant therapy (NAC) in individuals diagnosed with muscle invasive bladder cancer (MIBC).
• In March 2022, Protara Therapeutics, Inc. declared the dosing of the initial patient in ADVANCED-1, a Phase 1 clinical study assessing TARA-002, an investigational cell-based immunopotentiator developed for treating non-muscle invasive bladder cancer (NMIBC).
• In January 2022, Vaxiion Therapeutics shared that the U.S. Food and Drug Administration (FDA) approved the company’s Investigational New Drug application (IND) for VAX014, allowing its investigative use for treating solid tumors resistant to conventional therapies through intralesional treatment. VAX014 represents a pioneering recombinant bacterial minicell-based oncolytic immunotherapy.

Bladder cancer Overview

The most prevalent tumor of the urinary tract is bladder cancer (BC). The bladder wall is composed of many layers. Different cell types make up each layer, and bladder cancer (BC) starts when normal bladder lining cells, most often urothelial cells, alter and proliferate uncontrollably to create masses known as tumors.

Get a Free Sample PDF Report to know more about Bladder cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/bladder-cancer-pipeline-insight

Emerging Bladder cancer Drugs Under Different Phases of Clinical Development Include:

• RAG-01: Ractigen Therapeutics
• XNK03: XNK Therapeutics
• VAX014: Vaxiion Therapeutics
• MV-NIS: Vyriad, Inc.
• Lerapolturev: Istari Oncology Inc.
• TLD-1433: Theralase Technologies Inc.
• Futibatinib: Taiho Oncology, Inc.
• HX-008: Lepu Biopharma CO.,Ltd.
• TAR-200: Janssen Research & Development, LLC
• APL-1202: Asieris Pharmaceuticals
• N-803: ImmunityBio
• CG0070: CG Oncology
• UGN-102: UroGen
• Trilaciclib: G1 Therapeutics
• Tislelizumab: BeiGene

Bladder cancer Route of Administration

Bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Bladder cancer Molecule Type

Bladder cancer Products have been categorized under various Molecule types, such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Bladder cancer Pipeline Therapeutics Assessment

• Bladder cancer Assessment by Product Type
• Bladder cancer By Stage and Product Type
• Bladder cancer Assessment by Route of Administration
• Bladder cancer By Stage and Route of Administration
• Bladder cancer Assessment by Molecule Type
• Bladder cancer by Stage and Molecule Type

DelveInsight’s Bladder cancer Report covers around 100+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Bladder cancer product details are provided in the report. Download the Bladder cancer pipeline report to learn more about the emerging Bladder cancer therapies

Some of the key companies in the Bladder cancer Therapeutics Market include:

Key companies developing therapies for Bladder cancer are – Janssen Research & Development, LLC, Astellas Pharma, RemeGen Co., Ltd., UroGen Pharma Ltd., Flame Biosciences, Aura Biosciences, BeiGene, Incyte Corporation, CG Oncology, FKD Therapies, Bristol-Myers Squibb, LintonPharm Co., Ltd., ImmunityBio, Inc., Hamlet Pharma AB, Asieris Pharmaceuticals, Pfizer, Taizhou Hanzhong biomedical co. LTD, Protara Therapeutics, CicloMed LLC, enGene, Inc., Emtora Biosciences, Theralase Inc.,  Vaxiion Therapeutics, QED Therapeutics, G1 Therapeutics, AN0025, Kyowa Kirin, Inc., Infinity Pharmaceuticals, Shanghai Hengrui Pharmaceutical Co., Ltd., HiberCell, Inc., Ikena Oncology, Genentech, Fusion Pharmaceuticals, GI Innovation,SOTIO Biotech AG, Celon Pharma SA, 4D Pharma PLC, and others.

Bladder cancer Pipeline Analysis:

The Bladder cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Bladder cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bladder cancer Treatment.
• Bladder cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Bladder cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bladder cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Bladder cancer drugs and therapies

Bladder cancer Pipeline Market Drivers

• Increase in the number of patients suffering from non-muscle invasive bladder cancer, development of novel therapies and favorable government policies are some of the important factors that are fueling the Bladder cancer Market.

Bladder cancer Pipeline Market Barriers

• However, identifying the patient population with specific mutations for targeted therapy regimens, lack of awareness about the advanced cancer therapies and other factors are creating obstacles in the Bladder cancer Market growth.

Scope of Bladder cancer Pipeline Drug Insight    

• Coverage: Global
• Key Bladder cancer Companies: Ractigen Therapeutics, XNK Therapeutics, Vaxiion Therapeutics, Vyriad, Inc., Istari Oncology Inc., Theralase Technologies Inc., Taiho Oncology, Inc., Lepu Biopharma CO.,Ltd., Janssen Research & Development, LLC, Asieris Pharmaceuticals, ImmunityBio, CG Oncology, UroGen, G1 Therapeutics, BeiGene, and others
• Key Bladder cancer Therapies: RAG-01, XNK03, VAX014, MV-NIS, Lerapolturev, TLD-1433, Futibatinib, HX-008, TAR-200, APL-1202, N-803, CG0070, UGN-102, Trilaciclib, Tislelizumab, and others
• Bladder cancer Therapeutic Assessment: Bladder cancer current marketed and Bladder cancer emerging therapies
• Bladder cancer Market Dynamics: Bladder cancer market drivers and Bladder cancer market barriers 

Request for Sample PDF Report for Bladder cancer Pipeline Assessment and clinical trials

Table of Contents

1. Bladder cancer Report Introduction

2. Bladder cancer Executive Summary

3. Bladder cancer Overview

4. Bladder cancer- Analytical Perspective In-depth Commercial Assessment

5. Bladder cancer Pipeline Therapeutics

6. Bladder cancer Late Stage Products (Phase II/III)

7. Bladder cancer Mid Stage Products (Phase II)

8. Bladder cancer Early Stage Products (Phase I)

9. Bladder cancer Preclinical Stage Products

10. Bladder cancer Therapeutics Assessment

11. Bladder cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Bladder cancer Key Companies

14. Bladder cancer Key Products

15. Bladder cancer Unmet Needs

16 . Bladder cancer Market Drivers and Barriers

17. Bladder cancer Future Perspectives and Conclusion

18. Bladder cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bladder cancer Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Aura Biosciences, BeiGene, Incyte, CG Oncology, FKD Therapies